Navigation Links
S*BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets
Date:1/6/2009

S*BIO Receives $25 Million Upfront Payment and Equity Investment and Eligible to Receive Additional $525 Million in Option & License Fees and Milestone Payments

SINGAPORE, Jan. 6 /PRNewswire/ -- S*BIO Pte Ltd today announced that the company has entered into a Development Collaboration, and Option & License Agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize S*BIO's novel JAK2 inhibitors, SB1518 and SB1578.

Under the terms of the agreement, S*BIO is eligible to receive up to $550 million in combined equity purchase, option & license fees, and development and sales milestone payments. This includes an upfront payment and upfront equity purchase totaling $25 million. S*Bio is also eligible to receive up to double digit royalties on any sales.

S*BIO will perform all the clinical development activities for SB1518 and preclinical to clinical development activities for SB1578 during the option period. Onyx can elect to exercise its exclusive options for SB1518 and SB1578 at certain predetermined stages of development for each product separately and independently. Each option converts into an exclusive license for development and commercialization rights for SB1518 and SB1578 in all indications in the United States, Canada and Europe where Onyx will assume all of the associated development costs. S*BIO has a co-funding option with respect to these development costs in return for enhanced royalties on any future product sales. S*BIO retains rights to develop and commercialize SB1518 and SB1578 in the rest of the world.

The development of SB1518 will initially focus on the treatment of myelofibrosis and other myeloproliferative diseases. JAK2 inhibitors are implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases.

"We are pleased to work with Onyx Pharmaceuticals and increase available reso
'/>"/>

SOURCE S*BIO
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
2. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. MHA Announces Pegeen Butterfield, RN as Senior Vice President of Trade Relations
5. IMRIS announces first IMRISneuro project in Australia
6. Akrimax Pharmaceuticals Announces Manufacturing Partnership
7. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
8. American Asthma Foundation Announces Breakthrough Discovery
9. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
10. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
11. DiFUSION Technologies Announces Company Launch Focused on Surgical Site Infections (SSIs)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...ls for Swift Passage of H.R. 3961 to Secure the St...wire-USNewswire/ -- Statement Attributable to: J. ...sociation. ,, (Logo: http://www.newscom.com/c...ils the passage of the House health reform bill, w...nts and physicians and calls for swift passage of ...
(Date:11/8/2009)...P Praises House Passage of Health Care Reform Bill...icare, improve coverage for all Americans ,, C...he United States House of Representatives passed b...egislation that would strengthen Medicare for seni...that prices millions of Americans out of affordabl...
(Date:11/8/2009)...P Praises House Passage of Health Care Reform Bill...icare, improve coverage for all Americans ,, B...RY: Tonight the United States House of Representa...on that would strengthen Medicare for seniors and ...ces millions of Americans out of affordable health...
(Date:11/7/2009)...INGTON, Nov. 7 Karen Ig...ance Plans (AHIP), released the following statemen...th plans strongly support comprehensive health car...on by proposing a complete overhaul of how health ...sed guaranteed coverage, elimination of pre-existi...
(Date:11/7/2009)...TON, Nov. 7, The Americ...9 Benjamin Rush Award for Citizenship and Communit...ist from Chicago, IL. The award recognizes physici...nal call of duty to make an outstanding public ser...aff received the award today during the opening se...
Breaking Medicine News(10 mins):Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2
... need for Systech,s productized software , , BRUS... Packaging Execution Systems (PES) for the pharmac...g lines are installed, underway or contracted with...act. , , Driving Systech,s growth in Europe is d...
...ve suffered such problems, study finds , ,...boost the odds of developing rotator cuff problems...r injury running in families. , The finding is bas...ird cousins, can predict an individual,s risk. , "...
...e Featured March 7-12 in San Diego , , FAIRFAX,...logy (SIR) will present the latest research on tre...bone cancer; herniated disks; peripheral arterial ...on Center in San Diego, Calif. , , Highlights of...
...e Founder and President of Leventhal Consulting, ...ion executive weight loss consulting service for a...ke County (OH) Bar Association at 11:45 am today a... clients over the telephone, through e-mail, and i...
...e Visiting Nurse Association of Greater Philadelph...cation in hospice and palliative medicine from the...Way is the medical director of VNA,s Hospice of Ph... quality of health care by certifying internists a...
...ncourages parents across the country to confront t...ing Disorder Awareness Week February 22-28 , , ... when I came home from school. It said, ,I know y...ating disorder with a child can be incredibly diff...
Other Medicine News:Health News:Systech International Announces its 150th Serialization Line 2Health News:Genes May Help Drive Rotator Cuff Injury 2Health News:Genes May Help Drive Rotator Cuff Injury 3Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 2Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 3Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 4Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 5Health News:Mark Leventhal to Address the Lake County (OH) Bar Association 2Health News:Hospice of Philadelphia Medical Director, Deborah Way, MD, Earns Certification from the American Board of Internal Medicine 2Health News:The Renfrew Center Foundation Partners with 2008 Miss America Kirsten Haglund and Her Mom, Iora Haglund, to Empower Parents to Fight Eating Disorders 2Health News:The Renfrew Center Foundation Partners with 2008 Miss America Kirsten Haglund and Her Mom, Iora Haglund, to Empower Parents to Fight Eating Disorders 3
(Date:11/6/2009)..., NEW YORK, Nov. 6 Ker...hold a conference call on Tuesday, November 10, 20...009 financial results and business outlook for the...Officer of the Company, will host the call. Keryx...od in a press release to be issued prior to the ca...
(Date:11/6/2009)..., SAN DIEGO, Nov. 6 NexBio Inc.,...or Disease Control and Prevention (CDC), St. Louis...unced today the publication of two articles in the...hed studies suggest that DAS181 (Fludase ® ) ...tment and prevention of the Pandemic Influenza A(H...
(Date:11/5/2009)..., EATONTOWN, N.J., Nov. 5 /PRNewswire-FirstCall/...the emerging field of biologic products for regene...or the third quarter ended September 30, 2009. ,...s on the release of our three new biologic product...Technology and Plexur M® Innovative Grafting,...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Smokers Twice As Likely to Get TB 55170 1Smokers Twice As Likely to Get TB 55170 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 1FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 3FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 4FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 5FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 6FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 7FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 8FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 9FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 10Benchmark Brands Celebrates 20th Anniversary 55163 1Benchmark Brands Celebrates 20th Anniversary 55163 2
...TLE, Oct. 6 Dendreon Corporation (Nasdaq:,DNDN) w...6, 2008 at 9:00 AM,ET (6:00 AM PT) to review the o...notherapy for Prostate AdenoCarcinoma Treatment, a... (sipuleucel-T), the Company,s investigational,act...vanced prostate,cancer., Those interested may a...
...ington County, New Jersey is the newest study site...f Philadelphia today received a contract to manage.... Children,s Hospital will manage local,participat... County, New,Jersey. The study is funded by the Na...ipate approximately 1,000 families in Burlington,C...
Other Medicine Technology:Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2
13848 Buffer Solution pH 4.00 (250ml)
... convenient pH catheter calibration., ,pH cathete...edure. The Alpine Calibration kit contains dispos...ter for your convenience. Simply cut the end off ...soak. No measuring or pouring! Available in pH 4 ...
Bravo pH Receiver
Bravo Tubing/Filter Supplies
Medicine Products: